PSTI News Alert Pluristem Therapeutics (PSTI) 2.60 12/13/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pluristem Therapeutics (PSTI) 2.60 $PSTI

Will Pluristem Therapeutics (PSTI) Crush Estimates at Its Next Earnings Report? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:01AM CST
Pluristem Therapeutics has seen a nice streak of beating earnings estimates at the previous two reports and might be in a good position to beat earnings at its next report
PSTI: 2.60 (+0.01)

Critical Limb Ischemia - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/m55nsq/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Critical Limb Ischemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Critical Limb Ischemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aastrom Biosciences - AnGes MG - Apceth GmbH & Co - Athersys - Hemostemix - Human Stem Cells Institute - Juventas Therapeutics - Kasiak Research - Multi Gene Vascular Systems - NeoStem - Nuo Therapeutics - Pharmicell - Pluristem Therapeutics - ReNeuron Group - Stempeutics Research Private - TikoMed - ViroMed For more information visit http://www.researchandmarkets.com/research/m5...tical_limb
PSTI: 2.60 (+0.01)

Pluristem and Hadassah Medical Center Will Collaborate to Study Potential of PLX-RAD Cells to Improve Bone Marrow and Umbilical Cord Blood Transplant Outcomes
GlobeNewswire - Thu Dec 04, 2:00AM CST
Pluristem Therapeutics Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-based cell therapy products, announced today that it has entered into a long-term collaboration agreement with Hadassah Medical Center in Jerusalem. The medical center's Department of Bone Marrow Transplantation and Cancer Immunotherapy, headed by Professor Reuven Or, will use preclinical models to assess the potential efficacy of PLX-RAD cells for treatment and prevention of hematological deficiencies and complications of bone marrow and umbilical cord blood transplantation. PLX-RAD cells are Pluristem's second cell therapy product candidate.
PSTI: 2.60 (+0.01)

Exelixis Shares Down on COMET-2 Study Results on Cabozantinib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 1:29PM CST
Shares of Exelixis, Inc. (EXEL) dropped 10.2% after the company announced that the trial COMET-2 on cabozantinib did not meet its primary endpoint.
VRX: 138.71 (-0.18), PSTI: 2.60 (+0.01), EXEL: 1.40 (unch)

Pluristem wins patent for 3D cell expansion technology in Singapore
M2 - Mon Dec 01, 7:22AM CST
Cell therapy products company Pluristem Therapeutics (NasdaqCM STI) (Tel Aviv STI.TA) reported on Monday the receipt of the patent titled "Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy" in Singapore.
PSTI: 2.60 (+0.01)

Pluristem Granted Patent in Singapore for Its 3D Cell Expansion Technology
GlobeNewswire - Mon Dec 01, 2:00AM CST
Pluristem Therapeutics Inc. (Nasdaq STI) (TASE STI), a leading developer of placenta-based cell therapy products, announced today it has been granted a patent in Singapore titled "Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy."
PSTI: 2.60 (+0.01)

Pluristem's Dr. Ohad Karnieli to Present at Two Upcoming Scientific Conferences
GlobeNewswire - Tue Nov 25, 2:00AM CST
Pluristem Therapeutics Inc. (Nasdaq STI) (TASE STI), a leading developer of placenta-based cell therapy products, announced today that Dr. Ohad Karnieli, the Company's vice president of development and manufacturing, will present at two scientific conferences on the latest advancements in large-scale cell therapy manufacturing.
PSTI: 2.60 (+0.01)

Pluristem posts 1Q loss
Automated Insights - Fri Nov 21, 6:15AM CST
HAIFA, Israel (AP) _ Pluristem Therapeutics Inc. (PSTI) on Friday reported a loss of $5.9 million, or 9 cents per share, in its fiscal first quarter.
PSTI: 2.60 (+0.01)

Pluristem wins patents in Australia and New Zealand for placental cells for treating orthopedic, nerve injury and neurodegenerative diseases
M2 - Wed Nov 12, 6:25AM CST
Placenta cell therapy company Pluristem Therapeutics (NasdaqCM STI) (NasdaqCM STI.TA) disclosed on Wednesday the receipt of a patent in both Australia and New Zealand for the use of a specified population of placental cells for treating several medical indications.
PSTI: 2.60 (+0.01)

Pluristem Granted Patents in Australia and New Zealand for Use of Placental Cells in the Treatment of Multiple Indications
GlobeNewswire - Wed Nov 12, 2:35AM CST
Pluristem Therapeutics Inc. (Nasdaq STI) (TASE STI), a leading developer of placenta-based cell therapy products, announced today that it has been granted a patent in both Australia and New Zealand for the use of a specified population of placental cells for treating several medical indications. The patent, titled "Adherent cells from placenta and use of same in disease treatment" has been issued in Australia, Patent No. 2010322808, and in New Zealand, Patent No. 600651.
PSTI: 2.60 (+0.01)

Pluristem CEO Zami Aberman to Present at Two Regenerative Medicine Conferences in London on November 12 and 13, 2014
GlobeNewswire - Mon Nov 10, 2:00AM CST
London Regenerative Medicine Network Meeting
PSTI: 2.60 (+0.01)

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014 - 38 Companies & 67 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/rdllgl/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Athersys, Inc. - Seattle Genetics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Idera Pharmaceuticals, Inc. - Mesoblast Limited - Jazz Pharmaceuticals plc - Alexion Pharmaceuticals, Inc. - Soligenix, Inc. - NeoStem, Inc. - Pharmacyclics, Inc. - Pluristem Therapeutics Inc. - MediPost Co., Ltd. - Kamada Ltd. - R-Tech Ueno, Ltd. - Omni Bio Pharmaceutical Inc. - Alder Biopharmaceuticals Inc. - MSM Protein Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/rd...ersus_host
BIIB: 344.49 (+2.16), PCYC: 132.65 (-2.34), PSTI: 2.60 (+0.01), NBS: 3.58 (+0.31), ALDR: 25.27 (-1.46), IDRA: 3.84 (-0.03), SGEN: 32.25 (-1.49), JAZZ: 165.12 (-8.09), ALXN: 186.90 (-4.72), KMDA: 3.51 (-0.02), ATHX: 1.36 (+0.05), NVS: 93.52 (-0.82)

Pluristem Therapeutics Developing Off-The-Shelf Cell Therapy to Cure Blood Cancers and Treat Radiation Sickness
ACCESSWIRE - Wed Nov 05, 7:40AM CST
LOS ANGELES, CA / ACCESSWIRE / November 5, 2014 / Innovation is the root of Pluristem Therapeutics's (PSTI:NASDAQ) technology, and its latest offering, PLX-RAD cells represent a new line of allogenic off-the-shelf therapy with two distinct and vital applications - bone marrow transplant (BMT) and acute radiation syndrome (ARS). PLX-RAD cells are specifically engineered to treat blood cancers and restore healthy bone marrow function following chemotherapy, radiation therapy, and radiation exposure resulting from a nuclear or terrorist dirty bomb.
PSTI: 2.60 (+0.01)

The Spectranetics Corporation (SPNC) in Focus: Stock Soars 13.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 8:21AM CDT
The Spectranetics Corporation (SPNC) was a big mover last session, as the company saw its shares soar by over 13% on the day.
SPNC: 34.37 (+0.70), VRX: 138.71 (-0.18), PSTI: 2.60 (+0.01), MYL: 53.32 (-1.39)

Case Western Reserve University to Study Pluristem's PLX-RAD Cells in Umbilical Cord Blood Transplants for the Treatment of Blood Cancers and Genetic Diseases
GlobeNewswire - Mon Oct 27, 2:59AM CDT
Pluristem Therapeutics Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-derived cell therapy products, announced today that researchers at Case Western Reserve University will conduct a preclinical study of the Company's PLacental eXpanded (PLX)-RAD cells. The study will evaluate whether PLX-RAD cells increase the success rate of human umbilical cord blood transplantation.
PSTI: 2.60 (+0.01)

Japan Gives A Hug To The Cell Therapy Industry: R. Lee Buckler
Life Sciences Report - Seeking Alpha - Fri Oct 24, 7:21AM CDT
Last year, Japan rolled out the red carpet for cell therapy developers with new legislation designed to expedite development of regenerative medicine solutions for all manner of disease. In this interview with The Life Sciences Report , former...
PSTI: 2.60 (+0.01), UTHR: 129.37 (-1.86), OSIR: 12.92 (-0.04), ATHX: 1.36 (+0.05)

Alexion Beats on Earnings & Revenues in Q3, Guides Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 12:28PM CDT
Alexion (ALXN) reported higher than expected earnings in the quarter.
MDVN: 106.86 (-1.16), PSTI: 2.60 (+0.01), ALXN: 186.90 (-4.72), PDLI: 7.41 (-0.08)

Celgene Beats Q3 Earnings Estimates on High Revlimid Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 11:50AM CDT
Celgene (CELG) reported higher than expected earnings in the quarter.
MDVN: 106.86 (-1.16), PSTI: 2.60 (+0.01), PDLI: 7.41 (-0.08), CELG: 114.49 (-2.25)

Pluristem Advances Its Second Major Cell Therapy Product Line From Development to Large-Scale Manufacturing
GlobeNewswire - Tue Oct 21, 2:00AM CDT
Pluristem Therapeutics Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-based cell therapy products, announced today that it has completed development of its second major product line, and can now begin manufacturing the cells on a large-scale at its state-of-the art facility in order to meet demand for anticipated studies in a range of hematologic conditions. This second cell product candidate, called PLX-RAD, was created using Pluristem's proprietary three dimensional cell expansion technology platform. The Company's first product, PLX-PAD, is already in clinical trials for the treatment of peripheral artery disease, muscle injury and pulmonary arterial hypertension.
PSTI: 2.60 (+0.01)

Pluristem's Therapy for Muscle and Tendon Regeneration May Revolutionize Sports Medicine
ACCESSWIRE - Fri Oct 17, 7:00AM CDT
Los Angeles, CA / ACCESSWIRE / October 17, 2014 / With football season underway, my thoughts run to player injury and how it keeps good athletes off the field with few options for recovery except the stale advice and medicine doctors offer. Rotator cuff damage is a good example. Surgery is invasive and has serious consequences. Rest and recovery takes months. Whether or not talent will be restored is always a question. Enter the questionable treatments: Regenexx, is a privately-held company pandering to sports superstars with promises of stem cell therapy that can't be substantiated. However, there is an answer - Pluristem (NASDAQ STI), a leader in cell therapy, will soon conduct Phase I clinical trials for rotator cuff muscle and tendon regeneration that could bring sports medicine, already a $21 billion industry growing faster than the US GNP, into a new era. Pluristem's cell therapy has already shown efficacy in orthopedic medicine. In a successfully completed Phase I/II trial conducted at Germany's Charite University in Berlin under the auspices of Germany's Paul-Ehrlich Institut, the German equivalent of the FDA, Pluristem's PLX cells showed a 500% improvement over placebo in healing gluteal muscle injury.
PSTI: 2.60 (+0.01)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 23

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 290

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 136

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 258

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 157

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 530

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 124

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 424

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 19

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading

Top 5 Most Recently Viewed Articles

Trade Developments Impacting Global Stocks and Currencies

Updated Category News Views 225

Trade Developments Impacting Global Stocks During the latest trading session in Asia, futures for the S&P 500 and Nasdaq 100 showed positive momentum, increasing by 0.5% and 0.6% respectively. This positive trend comes after Friday's historic closing levels. The surge in optimism can be largely attributed to developments surrounding a trade agreement between the US and...

Continue Reading
Subaru Launches Gear for Good Initiative for Youth Soccer Growth

Updated Category News Views 152

Subaru Champions Youth Soccer with Gear for Good Initiative Subaru of America is proud to announce its engaging initiative, Gear for Good, aimed at nurturing the budding talent in youth soccer. This project represents Subaru's unwavering commitment to community involvement, ensuring that every child has access to the necessary tools to pursue their passion for soccer....

Continue Reading
Discover Nykredit's Upcoming Mortgage Bond Auction Insights

Updated Category News Views 306

Nykredit's Mortgage Bond Auction Overview Nykredit Realkredit A/S, a prominent financial institution, is organizing an exciting auction designed for interested investors. This event aims to enhance participation in the mortgage bond market, making it a notable opportunity for those seeking investment options. What to Expect at the Auction Scheduled for a future date, the...

Continue Reading
Paperclip Partners with Apis Productions for Robust Data Security

Updated Category News Views 106

Paperclip Collaborates with Apis Productions for Enhanced Security In an exciting new development, Paperclip, Inc. (OTCMKTS: PCPJ) has announced its partnership with Apis Productions to launch cutting-edge data security solutions. This collaboration focuses on integrating Paperclip’s innovative SAFE encryption technology within Apis Productions’ insurance technology...

Continue Reading
Medical Imaging Equipment Services Market Set for Growth Surge

Updated Category News Views 91

Overview of the Medical Imaging Equipment Services Market The Medical Imaging Equipment Services Market is set for a period of substantial growth, with projections indicating an increase from USD 60 billion in 2024 to USD 85 billion by 2031. This growth trajectory correlates with a compound annual growth rate (CAGR) of 5.0%. Several factors are contributing to this steady...

Continue Reading